Quarterly report · Q3
3353.TEDINET S100SM34
Period2023-03-01 → 2023-11-30
Filed2024-01-12
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥28.8bn | 2023-03-01 → 2023-11-30 | Cons. | Net sales |
| Revenue | ¥33.9bn | 2022-03-01 → 2023-02-28 | Cons. | Net sales (5-year summary) |
| Revenue | ¥25.4bn | 2022-03-01 → 2022-11-30 | Cons. | Net sales |
| Operating income | ¥1.1bn | 2023-03-01 → 2023-11-30 | Cons. | Operating income |
| Operating income | ¥706m | 2022-03-01 → 2022-11-30 | Cons. | Operating income |
| Ordinary income | ¥1.2bn | 2023-03-01 → 2023-11-30 | Cons. | Ordinary income |
| Ordinary income | ¥1.2bn | 2022-03-01 → 2023-02-28 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥888m | 2022-03-01 → 2022-11-30 | Cons. | Ordinary income |
| Profit before tax | ¥1.3bn | 2023-03-01 → 2023-11-30 | Cons. | Income before income taxes |
| Profit before tax | ¥998m | 2022-03-01 → 2022-11-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥812m | 2023-03-01 → 2023-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥760m | 2022-03-01 → 2023-02-28 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥597m | 2022-03-01 → 2022-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥847m | 2023-03-01 → 2023-11-30 | Cons. | Profit loss |
| Net income | ¥623m | 2022-03-01 → 2022-11-30 | Cons. | Profit loss |
| Total assets | ¥32.8bn | at 2023-11-30 | Cons. | Assets |
| Total assets | ¥27.5bn | at 2023-02-28 | Cons. | Assets |
| Total assets | ¥28.0bn | at 2022-11-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥19.4bn | at 2023-11-30 | Cons. | Liabilities |
| Total liabilities | ¥14.9bn | at 2023-02-28 | Cons. | Liabilities |
| Net assets / equity | ¥13.4bn | at 2023-11-30 | Cons. | Net assets |
| Net assets / equity | ¥12.6bn | at 2023-02-28 | Cons. | Net assets |
| Net assets / equity | ¥12.4bn | at 2022-11-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥7.8bn | at 2023-11-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥6.4bn | at 2023-02-28 | Cons. | Cash and deposits |
| EPS (basic) | ¥216.2 | 2023-03-01 → 2023-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥97.93 | 2023-09-01 → 2023-11-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥202.2 | 2022-03-01 → 2023-02-28 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥159 | 2022-03-01 → 2022-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥59.34 | 2022-09-01 → 2022-11-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 39.1% | at 2023-11-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 43.8% | at 2023-02-28 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 42.3% | at 2022-11-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 44
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-03-01 → 2023-11-30 | −¥670m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-03-01 → 2023-11-30 | −¥670m |
| Reconciling Itemsreconciling | segment profit | 2023-03-01 → 2023-11-30 | −¥544m |
| jpcrp040300-q3r_E03443-000Dispensing Pharmacyreportable segment | revenue | 2023-03-01 → 2023-11-30 | ¥17.7bn |
| jpcrp040300-q3r_E03443-000Dispensing Pharmacyreportable segment | revenue external | 2023-03-01 → 2023-11-30 | ¥17.7bn |
| jpcrp040300-q3r_E03443-000Dispensing Pharmacyreportable segment | segment profit | 2023-03-01 → 2023-11-30 | ¥1.3bn |
| jpcrp040300-q3r_E03443-000Health Carereportable segment | revenue | 2023-03-01 → 2023-11-30 | ¥5.8bn |
| jpcrp040300-q3r_E03443-000Health Carereportable segment | revenue external | 2023-03-01 → 2023-11-30 | ¥5.8bn |
| jpcrp040300-q3r_E03443-000Health Carereportable segment | revenue intersegment | 2023-03-01 → 2023-11-30 | ¥450,000 |
| jpcrp040300-q3r_E03443-000Health Carereportable segment | segment profit | 2023-03-01 → 2023-11-30 | ¥160m |
| jpcrp040300-q3r_E03443-000Medical Products Wholesalereportable segment | revenue | 2023-03-01 → 2023-11-30 | ¥5.7bn |
| jpcrp040300-q3r_E03443-000Medical Products Wholesalereportable segment | revenue external | 2023-03-01 → 2023-11-30 | ¥5.1bn |
| jpcrp040300-q3r_E03443-000Medical Products Wholesalereportable segment | revenue intersegment | 2023-03-01 → 2023-11-30 | ¥666m |
| jpcrp040300-q3r_E03443-000Medical Products Wholesalereportable segment | segment profit | 2023-03-01 → 2023-11-30 | ¥99m |
| jpcrp040300-q3r_E03443-000Real Estatereportable segment | revenue | 2023-03-01 → 2023-11-30 | ¥140m |
| jpcrp040300-q3r_E03443-000Real Estatereportable segment | revenue external | 2023-03-01 → 2023-11-30 | ¥136m |
| jpcrp040300-q3r_E03443-000Real Estatereportable segment | revenue intersegment | 2023-03-01 → 2023-11-30 | ¥3m |
| jpcrp040300-q3r_E03443-000Real Estatereportable segment | segment profit | 2023-03-01 → 2023-11-30 | ¥99m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-03-01 → 2023-11-30 | ¥29.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-03-01 → 2023-11-30 | ¥28.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-03-01 → 2023-11-30 | ¥670m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-03-01 → 2023-11-30 | ¥1.6bn |
| Reconciling Itemsreconciling | revenue | 2022-03-01 → 2022-11-30 | −¥744m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-03-01 → 2022-11-30 | −¥744m |
| Reconciling Itemsreconciling | segment profit | 2022-03-01 → 2022-11-30 | −¥557m |
| jpcrp040300-q3r_E03443-000Dispensing Pharmacyreportable segment | revenue | 2022-03-01 → 2022-11-30 | ¥17.3bn |
| jpcrp040300-q3r_E03443-000Dispensing Pharmacyreportable segment | revenue external | 2022-03-01 → 2022-11-30 | ¥17.3bn |
| jpcrp040300-q3r_E03443-000Dispensing Pharmacyreportable segment | segment profit | 2022-03-01 → 2022-11-30 | ¥1.1bn |
| jpcrp040300-q3r_E03443-000Health Carereportable segment | revenue | 2022-03-01 → 2022-11-30 | ¥5.8bn |
| jpcrp040300-q3r_E03443-000Health Carereportable segment | revenue external | 2022-03-01 → 2022-11-30 | ¥5.8bn |
| jpcrp040300-q3r_E03443-000Health Carereportable segment | revenue intersegment | 2022-03-01 → 2022-11-30 | ¥450,000 |
| jpcrp040300-q3r_E03443-000Health Carereportable segment | segment profit | 2022-03-01 → 2022-11-30 | ¥35m |
| jpcrp040300-q3r_E03443-000Medical Products Wholesalereportable segment | revenue | 2022-03-01 → 2022-11-30 | ¥2.9bn |
| jpcrp040300-q3r_E03443-000Medical Products Wholesalereportable segment | revenue external | 2022-03-01 → 2022-11-30 | ¥2.2bn |
| jpcrp040300-q3r_E03443-000Medical Products Wholesalereportable segment | revenue intersegment | 2022-03-01 → 2022-11-30 | ¥742m |
| jpcrp040300-q3r_E03443-000Medical Products Wholesalereportable segment | segment profit | 2022-03-01 → 2022-11-30 | ¥29m |
| jpcrp040300-q3r_E03443-000Real Estatereportable segment | revenue | 2022-03-01 → 2022-11-30 | ¥142m |
| jpcrp040300-q3r_E03443-000Real Estatereportable segment | revenue external | 2022-03-01 → 2022-11-30 | ¥140m |
| jpcrp040300-q3r_E03443-000Real Estatereportable segment | revenue intersegment | 2022-03-01 → 2022-11-30 | ¥1m |
| jpcrp040300-q3r_E03443-000Real Estatereportable segment | segment profit | 2022-03-01 → 2022-11-30 | ¥92m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-03-01 → 2022-11-30 | ¥26.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-03-01 → 2022-11-30 | ¥25.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-03-01 → 2022-11-30 | ¥744m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-03-01 → 2022-11-30 | ¥1.3bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 370
| Item | Context | Value | Unit |
|---|---|---|---|
| Operating income | Prior1YTDDuration_jpcrp040300-q3r_E03443-000RealEstateReportableSegmentsMember | 91688000 | JPY |
| Operating income | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 1262705000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | -557151000 | JPY |
| Operating income | Prior1YTDDuration | 705553000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q3r_E03443-000DispensingPharmacyReportableSegmentsMember | 17706171000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q3r_E03443-000HealthCareReportableSegmentsMember | 5845728000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q3r_E03443-000MedicalProductsWholesaleReportableSegmentsMember | 5081873000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q3r_E03443-000RealEstateReportableSegmentsMember | 136028000 | JPY |
| Revenues from external customers | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 28769800000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 28769800000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q3r_E03443-000DispensingPharmacyReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q3r_E03443-000HealthCareReportableSegmentsMember | 450000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q3r_E03443-000MedicalProductsWholesaleReportableSegmentsMember | 666369000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q3r_E03443-000RealEstateReportableSegmentsMember | 3491000 | JPY |
| Transactions with other segments | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 670310000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | -670310000 | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q3r_E03443-000DispensingPharmacyReportableSegmentsMember | 17706171000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q3r_E03443-000HealthCareReportableSegmentsMember | 5846178000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q3r_E03443-000MedicalProductsWholesaleReportableSegmentsMember | 5748243000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q3r_E03443-000RealEstateReportableSegmentsMember | 139519000 | JPY |
| Net sales | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 29440111000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | -670310000 | JPY |
| Net sales | CurrentYTDDuration | 28769800000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q3r_E03443-000DispensingPharmacyReportableSegmentsMember | 1264459000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q3r_E03443-000HealthCareReportableSegmentsMember | 160092000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q3r_E03443-000MedicalProductsWholesaleReportableSegmentsMember | 99124000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q3r_E03443-000RealEstateReportableSegmentsMember | 98903000 | JPY |
| Operating income | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 1622580000 | JPY |
| Operating income | CurrentYTDDuration_ReconcilingItemsMember | -544157000 | JPY |
| Operating income | CurrentYTDDuration | 1078423000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)四半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の４の７第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)東海財務局長 | |
| Filing date cover page | FilingDateInstant | 2024-01-12 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第39期第３四半期（自 2023年９月１日 至 2023年11月30日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)株式会社メディカル一光グループ | |
| Company name in english cover page | FilingDateInstant | Medical Ikkou Group Co.,Ltd. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 南野 利久 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)三重県津市西丸之内36番25号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)059－226－1193（代表） | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)上席執行役員 経理部・管理部担当 兼 財務・ＩＲ部長 遠山 邦彦 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)三重県津市西丸之内36番25号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | Original text (Japanese)059－226－1193（代表） | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)上席執行役員 経理部・管理部担当 兼 財務・ＩＲ部長 遠山 邦彦 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E03443 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 33530 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |